Free Trial
→ $100 Trillion “AI Metal” Found in American Ghost Town (From Brownstone Research) (Ad)tc pixel
NASDAQ:IBRX

ImmunityBio 11/8/2023 Earnings Report

ImmunityBio logo
$2.50 -0.09 (-3.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.52 +0.02 (+0.84%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

ImmunityBio EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

ImmunityBio Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImmunityBio Announcement Details

Quarter
Date
11/8/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

ImmunityBio's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

ImmunityBio Earnings Headlines

ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients
September 20, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/immunitybio-s-ibrx-anktiva-shows-survival-gains-in-lung-cancer-patients/ar-AA1MWBuA
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals
September 17, 2025  |  msn.comhttps://www.msn.com/en-us/health/diseases-and-conditions/immunitybio-stock-breaks-out-of-long-slump-tests-3-zone-ex-ubs-analyst-flags-huge-bullish-signals/ar-AA1MIeBP
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
September 24 at 2:00 AM  |  Brownstone Research (Ad)
H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8
September 15, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/hc-wainwright-reiterates-buy-rating-on-immunitybio-keeps-pt-at-8/ar-AA1MzXez
ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking
September 11, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4822139-immunitybio-still-too-early-to-judge-anktiva-although-clock-is-ticking
ImmunityBio study shows ANKTIVA reverses lymphopenia, extends survival
September 8, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/immunitybio-study-shows-anktiva-reverses-lymphopenia-extends-survival/ar-AA1M85dd
See More ImmunityBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImmunityBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmunityBio and other key companies, straight to your email.

About ImmunityBio

ImmunityBio (NASDAQ:IBRX) is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. Anktiva is being evaluated in combination with tumor-targeting monoclonal antibodies and immune checkpoint inhibitors for treatment of non–muscle-invasive bladder cancer as well as other solid tumors. In parallel, ImmunityBio is advancing novel T cell receptor (TCR) therapies and off-the-shelf NK cell products aimed at solid and hematologic malignancies.

Beyond oncology, the company has pursued viral-vectored vaccine candidates for infectious diseases, including a Phase 1 program for COVID-19. These efforts leverage a proprietary human adenovirus (hAd5) backbone intended to elicit robust cellular and humoral immune responses. ImmunityBio’s integrated approach combines cell engineering, cytokine biology and vaccine technology to build a diversified pipeline across multiple therapeutic areas.

Founded as NantKwest and rebranded to ImmunityBio in 2020, the company operates under the leadership of CEO Tarek Tantawi and was co-founded by biotech entrepreneur Dr. Patrick Soon-Shiong. Headquartered in Culver City, California, ImmunityBio conducts preclinical research and clinical trials in North America, Europe and Australia. The company maintains collaborations with academic institutions, government agencies and industry partners to accelerate development and regulatory filings for its immunotherapy candidates.

View ImmunityBio Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles